Effects of Interfractional Anatomical Changes on Water-Equivalent Pathlength in Charged-Particle Radiotherapy of Lung Cancer

  • MORI Shinichiro
    Massachusetts General Hospital, Harvard Medical School, Department of Radiation Oncology
  • LU Hsiao-Ming
    Massachusetts General Hospital, Harvard Medical School, Department of Radiation Oncology
  • WOLFGANG John A.
    Massachusetts General Hospital, Harvard Medical School, Department of Radiation Oncology
  • CHOI Noah C.
    Massachusetts General Hospital, Harvard Medical School, Department of Radiation Oncology
  • CHEN George T. Y.
    Massachusetts General Hospital, Harvard Medical School, Department of Radiation Oncology

この論文をさがす

抄録

Intrafractional motion and interfractional changes affect the accuracy of the delivered dose in radiotherapy, particularly in charged-particle radiotherapy. Most recent studies are focused on intrafractional motion (respiratory motion). Here, we report a quantitative simulation analysis of the effects of interfractional changes on water-equivalent pathlength (WEL) in charged-particle lung therapy. Serial four-dimensional (4D) CT scans were performed under free breathing conditions; the time span between the first and second 4DCT scans was five weeks. We quantified WEL changes between the first and second CT scans due to interfractional changes (tumor shrinkage and tissue density changes) and compared the particle-beam-stopping point between the serial 4DCT scans with use of the same initial bolus. Both tumor-shrinkage and lung-density changes were observed in a single patient over the course of therapy. The lung density decreased by approximately 0.1 g/cm3 between the first and second-CT scans, resulting in a 1.5 cm WEL changes. Tumor shrinkage resulted in approximately 3 cm WEL changes. If the same initial bolus and plan were used through the treatment course, an unexpected significant beam overshoot would occur by interfractional changes due to tumor shrinkage and lung density variation.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (35)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ